This therapeutic area records numbers of trials initiated in infectious diseases. The UK is leading as a site for infectious diseases clinical research, behind the US.
Data was collected from Cortellis Clinical Trial Intelligence, Clarivate Analytics using the following criteria: trial start date (1st January 2012 – 31st December 2016), phase (I, II, III), and country (UK, Spain, Germany, France, Italy, Poland, USA, Canada, Australia, China, Brasil, South Africa, Switzerland and Japan). Only trials related to pharmaceutical drug development and molecular/biological entities were included. Only commercial trials were included. Collaborative trials were only included if one or more partners were a commercial organisation. All therapeutic areas were included in this analysis. This analysis focused on infectious disease only. Trials across multiple therapy areas were only included once. The therapy area in which they were included was determined by the trial’s main purpose for study.
Phase not specified trials were excluded.
Only trials related to pharmaceutical drug development and molecular/ biological entities were included.
Where a company was included as a sponsor or collaborator, the trial was included, even if an academic institution was also listed.
Trials across multiple therapy areas were only included in their main therapy area.
SOURCE: Cortellis Clinical Trial Intelligence from Clarivate Analytics
2012-2014 data accessed March – April 2017.
2015 data accessed December 2017.
2016-2017 data accessed December 2018.